Efficacy of Monthly Oral Ibandronate Versus Quarterly Intravenous Ibandronate for the Treatment of Female Osteoporosis in Korean Patients

초록

Objective: To compare the efficacy of monthly oral ibandronate 150 mg to quarterly intravenous (IV) ibandronate 3 mg for the treatment of female osteoporosis in Korean patients. Methods: 77 Korean women over 65 years old with primary osteoporosis were studied retrospectively. The oral group included 32 patients, and the IV group included 45 patients. Clinical characteristics including age, sex, comorbidities, incidence of vertebral fractures and adverse events were evaluated for a year. Bone mineral density (BMD) of the lumbar spine (L1-4) and femoral neck were measured at baseline, 6 and 12 months. The efficacy variables were the percentage changes from baseline in mean lumbar spine and femoral neck BMD at 12 months. Results: There was no significant demographic difference between two groups. The mean percentage change (95% confidence interval [CI]) in lumbar spine BMD at 12 months was 12.85% (11.67-14.04) for the oral group and 12.84% (11.66- 14.02) for the IV group. The mean percentage change in femoral neck BMD at 12 months was 2.68% (1.19-4.17) with oral ibandronate and 3.51% (2.14-4.89) with IV ibandronate. The least squares mean difference between the two groups was within -1.6, showing similar results between two regimens. Conclusion: Monthly oral ibandronate and quarterly IV ibandronate showed similar efficacy with changes in BMD and occurrence of vertebral fractures for the treatment of female osteoporosis in Korean patients. However, IV ibandronate had less GI-related complications. Therefore, quarterly IV ibandronate is considered to be more effective than monthly oral bisphosphonate in patients who have poor adherence to oral ibandronate.

키워드